神经血管功能障碍与阿尔茨海默氏病中的Aβ之间的合作
Niya Wang1,2, Xiang Yang3, Zhong Zhao1,2
1Department of Neurology, The First People's Hospital of Yunnan Province, Kunming, China.
Frontiers in molecular neuroscience
|September 1, 2023
概括
阿尔茨海默病 (AD) 研究的重点从粉样蛋白β (Aβ) 转移到血管功能障碍. 血管损伤可能先于Aβ,突出了神经血管单元在AD病变发生中的作用.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 血管生物学 血管生物学
背景情况:
- 粉样β (Aβ) 假设,曾经是阿尔茨海默病 (AD) 病原体的核心,越来越多地受到临床试验失败的挑战.
- 新兴证据表明,血管系统功能障碍在阿尔茨海默病中起着关键作用,血管损伤可能会先于Aβ和神经纤维质结 (NFT) 沉积.
研究的目的:
- 审查阿尔茨海默病 (AD) 中的粉样β (Aβ) 和神经血管功能之间的复杂关系.
- 探索血管功能障碍作为AD的潜在触发因素或贡献者的作用.
- 突出神经血管单元 (NVU) 在理解AD病理生理学的重要性.
主要方法:
- 关于阿尔茨海默病 (AD) 和血管贡献的最新科学文献的综述.
- 对研究的分析,研究血管血动力学,细胞功能的变化,覆盖范围,以及AD中血脑屏障 (BBB) 透性的研究.
- 检查Aβ与神经血管单元 (NVU) 之间的相互作用.
主要成果:
- 阿尔茨海默病 (AD) 与各种血管功能障碍有关,包括改变的血液动力学,细胞功能,血管覆盖和血脑屏障 (BBB) 透性.
- 血管缺陷可以导致Aβ沉积,神经毒性,质激活和代谢功能障碍.
- Aβ和氧化应激会加剧血管损伤,从而产生有害的反循环.
结论:
- 神经血管单元 (NVU) 相互作用对于理解阿尔茨海默病 (AD) 病理生理学至关重要.
- 血管功能障碍是阿尔茨海默病的一个重要因素,可能是Aβ病理的前身或相互作用.
- 针对血管健康可能为阿尔茨海默病 (AD) 提供新的治疗策略.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.5K
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
相关概念视频
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
